Anti-b7-h3 compounds and methods of use

By developing the binding of anti-B7-H3 affinity to a targeting component or imaging component, the penetration and stability of antibodies when targeting tumors are solved, and efficient B7-H3 binding and targeted therapeutic effects are achieved.

CN118922446APending Publication Date: 2024-11-08REGENTS OF THE UNIVERSITY OF MINNESOTA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380029547.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-01-24
Filing Date
2023-01-24
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing antibodies have poor permeability, thermal instability and complex structures when targeting solid tumors, resulting in poor signal-to-noise ratios and difficulties in use in cells, especially in the production of multispecific forms of protein fusions.

Method used

Anti-B7-H3 compounds were developed, including anti-B7-H3 affinants, which have a structure similar to the helical surface of the antibody CDR, able to bind to the extracellular domain of B7-H3 and divide cells by magnetically activating the cells. Selection and fluorescence-activated cell sorting for selection and purification, combining targeted components, imaging components or small molecule drugs for targeted therapy and diagnosis.

Benefits of technology

It achieves functional characteristics similar to antibodies, has high affinity and stability, and can effectively bind B7-H3, which is suitable for targeted treatment and diagnosis, avoiding the limitations of antibodies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922446A_ABST
    Figure CN118922446A_ABST
Patent Text Reader

Abstract

The anti-B7-H3 compound comprises an anti-B7-H3 affinity body. The anti-B7-H3 compounds may include one or more functional components, such as a targeting component, an imaging component, an enzyme, or a small molecule drug. A composition comprising anti-B7-H3 may be administered to a subject. The subject may have or be at risk of having a tumor or cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application Serial No. 63 / 302,290, filed on January 24, 2022, which is incorporated herein by reference in its entirety.

[0003] Government funding

[0004] This invention was made with government support under Grant EB023339 awarded by the National Institutes of Health. The government has certain rights in this invention.

[0005] Sequence Listing

[0006] This application contains a sequence listing electronically submitted to the United States Patent and Trademark Office via Patent Center in the form of an XML file entitled "0110_000692WO01.xml", 49.6 kilobytes in size and created on January 22, 2023. Since the sequence listing is submitted electronically, the electronically submitted sequence listing serves as both a paper copy required by 37 CFR §1.821(c) and a CRF required by §1.821(e). The information contained in the sequence listing is incorporated herein by reference. Summary of the invention

[0007] In one aspect, the present disclosure describes an anti-B7-H3 compound. The anti-B7-H3 compound includes an anti-B7-H3 affinity body. The anti-B7-H3 affinity body includes an amino acid sequence of SEQ ID NO: 2, an amino acid sequence having at least 90% sequence similarity to SEQ ID NO: 2, or an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 2.

[0008] In one or more embodiments, the anti-B7-H3 affibody comprises any of the following amino acid sequences: SEQ ID NO:3; SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10; SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13; SEQ ID NO:14, SEQ ID NO:15; SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35 NO: 34. An amino acid sequence having at least 90% sequence similarity to any of the listed sequences or an amino acid sequence having at least 90% sequence identity to any of the listed sequences.

[0009] In one or more embodiments, the anti-B7-H3 compound comprises a first functional component operably linked to a B7-H3 affibody. In one or more embodiments, the first functional component comprises a targeting component, an imaging component, an enzyme, or a small molecule drug.

[0010] In one or more embodiments, the anti-B7-H3 compound may include a second functional component operably connected to the anti-B7-H3 affibody. In one or more embodiments, the second functional component includes a targeting component, an imaging component, an enzyme, or a small molecule drug. In one or more embodiments, the first functional component is directly connected to the anti-B7-H3 affibody, and the second functional component is directly connected to the anti-B7-H3 affibody. In one or more embodiments, the first functional component is directly connected to the anti-B7-H3 affibody, and the second functional component is directly connected to the first functional component.

[0011] In another aspect, the present disclosure describes a composition comprising an anti-B7-H3 compound and a pharmaceutically acceptable carrier.

[0012] In another aspect, the present disclosure describes a method comprising administering to a subject a composition comprising an anti-B7-H3 compound. In one or more embodiments, the subject suffers from a tumor. In one or more embodiments, the subject suffers from cancer. In one or more embodiments, the composition is administered before, simultaneously with, or after chemotherapy, surgical resection of the tumor, or radiotherapy. In one or more embodiments, the method further comprises a detection imaging component to detect an anti-B7-H3 compound bound to B7-H3 expressed by a cell. In one or more embodiments, the cell is a cancer cell.

[0013] The above summary of the invention is not intended to describe each disclosed embodiment or each implementation of the present invention. The following description more specifically illustrates illustrative embodiments. In several places throughout this application, guidance is provided by lists of examples, which can be used in various combinations. In each case, the enumerated lists serve only as representative groups and should not be construed as exclusive lists. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1. Affimer (ABY) binders of enriched B7-H3. (A) After three magnetic activated cell sorting (MACS) selections (populations 0.1, 0.2, 0.3 on the x-axis), yeast with soluble B7-H3 extracellular domains showed enrichment for B7-H3 targets over negative Renilla reniformis green fluorescent protein (rrGFP) and avidin beads. The enriched ABY population was selected for fluorescence activated cell sorting (FACS) for B7-H3 (producing population 0.4 on the x-axis). ND means no data because the binding to avidin beads and negative rrGFP was not analyzed in this sorting. The 0.4 population ABY library was extracted and error-prone PCR was performed, and then electroporated back into the yeast. The mutant untreated library was MACS selected (producing 1.1 population on the x-axis), and then monovalent MACS selected with 100nM recombinant human B7-H3 (producing 1.2 population on the x-axis). The remaining selections were performed via FACS (to obtain populations 1.3 and 1.4). (B) After three MACS selections, yeast was incubated with 50 nM recombinant human B7-H3 extracellular domain and then incubated with streptavidin-Alexa Fluor 647. ABY display was quantified with mouse anti-c-Myc antibody and goat anti-mouse Alexa Fluor 488. Flow cytometry analysis of 10,000 random variants is shown (population 0.4). (C) The enriched population was labeled with biotin-B7-H3 cell lysate, streptavidin-AF647 and chicken anti-c-Myc-FITC. The collected cells produced population 1.4. The boxes in (B) and (C) are cells collected during FACS sorting.

[0015] Figure 2. Protease and thermostability of the enriched ABY population that generated population 1.5. (A) The affibody library was mixed with 1×10 -6 Units / μL of proteinase K were incubated at 55°C for 10 minutes, followed by incubation with biotinylated detergent-solubilized MS1-B7-H3 cell lysate and labeled with streptavidin-Alexa Fluor 647. The top 0.5% of B7-H3 binders (grey boxes) were selected via flow cytometry. (B) Affibody libraries were incubated with proteinase K (+ proteinase) or without proteinase K (control) at 55°C, followed by incubation with biotinylated B7-H3 lysate. B7-H3 binding was slightly reduced for the + proteinase sample compared to the control, indicating that some variants are susceptible to proteinase K and elevated temperature.

[0016] Figure 3Sequences of B7-H3 binding affibodies evolved in .0.4, 1.4, and 1.5 populations. ABY025 represents the affibody sequence (SEQ ID NO: 18) from which the affibodies of the present disclosure are derived (see Design of an Optimized Scaffold for Affibody Molecules, 2010 (doi: 10.1016 / j.jmb.2010.03.002). Affibody library design is also shown. Eight colonies in the 0.4 population were sequenced (0.4.1 = SEQ ID NO: 4; 0.4.2 = SEQ ID NO: 5; 0.4.3 = SEQ ID NO: 6; 0.4.4 = SEQ ID NO: 7; 0.4.5 = SEQ ID NO: 8; 0.4.6 = SEQ ID NO: 9; 0.4.7 = SEQ ID NO: 10), of which 0.4.2 was observed twice (indicated by "x2"). The population showed different amino acid sequences between the variants. Ten colonies in the 1.4 population were sequenced (1.4.1 = SEQ ID NO:11; 1.4.2 = SEQ ID NO:12; 1.4.3 = SEQ ID NO:13; 1.4.4 = SEQ ID NO:14; 1.4.5 = SEQ ID NO:15; 1.4.6 = SEQ ID NO:16; 1.4.7 = SEQ ID NO:17; 1.4.8 = SEQ ID NO:18), of which 1.4.1 and 1.4.2 were observed twice (indicated by "x2"). Seven colonies in the 1.5 population were sequenced (1.5.1 = SEQ ID NO:19; 1.5.2 = SEQ ID NO:20), of which 1.5.1 was observed 5 times (indicated by "x5") and 1.5.2 was observed 2 times (indicated by "x2"). The amino acid diversity decreased and began to show the dominant clones present in the final enriched B7-H3 binding affibody population.

[0017] Figure 4 . ABY 1.5.2 (SEQ ID NO: 20) and GSG3SG3KG3GT (GSGGGSGGGKGGGGT) (SEQ ID NO: 35) linker and sortase A 60-206 Genetic combination and production in bacteria. ABY 1.5.2-L 15 -K of SrtA d The error bars show the standard error and each concentration was repeated at least twice.

[0018] Figure 5The sequences of the best performers after mutation of the 1.5 population and subsequent sorting by affinity sorting, affinity sorting, specificity sorting, and stability sorting are shown. The sequence space shows variability compared to Affibody 1.5.1 of the 1.5 population (see Figure 3 ), except Otu8 and Otu394, which are point mutants of 1.5.1.

[0019] Figure 6 The top ranked variants are shown (sequences are shown in Figure 5 Relative enrichment at each sorting step and weighted mean z-scores are shown in Figure 1 (middle). Values ​​greater than 1 indicate enrichment; values ​​less than 1 indicate depletion. The color bar for affinity enrichment ranges from 1–M+2SD because the mean (M) is slightly less than 1. The color bars for specificity, stability, and frequency are shown as M–M+2SD. The z-scores are shown as 1-10.

[0020] Figure 7 is a graph showing the relative frequency of the top Affibodies after each sort (affinity sort, affinity sort, specificity sort, and stability sort). Each line represents a single variant. The selected variants are denoted by Figure 5 The sequence name tag in . DETAILED DESCRIPTION

[0021] The present disclosure describes anti-B7-H3 affibody, a compound including at least one anti-B7-H3 affibody and a method for using such a compound. As used herein, the term "anti-B7-H3 compound" refers to a compound including an anti-B7-H3 affibody or an anti-B7-H3 affibody itself. The exemplary platform for using anti-B7-H3 compounds includes but is not limited to chimeric antigen receptor therapy (e.g., CAR-NK therapy, CAR-T therapy, CAR-macrophage therapy, etc.), multispecific immune cell adapter technology (e.g., bispecific killer adapter, trispecific killer adapter, bispecific T cell adapter, trispecific T cell adapter, etc.), targeted immunotherapy (e.g., targeted ADAM17 blocker (TAB) therapy), therapeutic agent delivery (e.g., antibody-drug conjugate, therapeutic radioisotope delivery, toxin delivery, cytokine delivery, chemokine delivery), imaging technology (labeled construct and / or labeled radioisotope delivery) or cell and / or ligand capture technology (e.g., ELISA, etc.).

[0022] B7 homolog 3 (B7-H3), also known as cluster of differentiation 276 (CD276), is a human protein encoded by the CD276 gene. The B7-H3 protein is a 316 amino acid long type I transmembrane protein that exists in two isoforms (determined by its extracellular domain). B7-H3 mRNA is expressed in most normal tissues. In contrast, since the B7-H3 protein is post-transcriptionally regulated by microRNAs, its expression on normal tissues is very limited. In normal tissues, B7-H3 plays a major inhibitory role in adaptive immunity, inhibiting T cell activation and proliferation. Therefore, B7-H3 is an important immune checkpoint inhibitor of T cell function, a tumor vascular biomarker, and is overexpressed in a variety of cancers, including clear cell renal cell carcinoma, cutaneous melanoma, diffuse intrinsic pontine glioma, hypopharyngeal squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, prostate cancer, and pancreatic cancer. The expression of B7-H3 is associated with tumor growth and metastasis, and may ultimately lead to poor clinical prognosis.

[0023] Molecules that specifically recognize certain targets and have high affinity can be used in many clinical (e.g., diagnosis and / or treatment) and biotechnology applications. Generally, antibodies have been used in many of these applications, but antibodies have certain characteristics that may become disadvantages in certain applications. The limitations of antibodies have promoted the research of alternative protein scaffolds that enable people to effectively produce improved binding molecules. For example, in the context of targeting solid tumors, antibodies (usually about 150 kDa for immunoglobulin G (IgG)) may exhibit poor extravasation from the vascular system, poor penetration through tissues and / or long plasma clearance half-life due to their size, at least in part, which may lead to poor signal-to-noise ratios, especially for diagnostic imaging. Antibodies may also exhibit thermal instability, which may lead to loss of effectiveness due to denaturation and / or aggregation. In addition, antibodies are usually prepared in mammalian cultures because many antibodies have disulfide bonds, glycosylation and / or multi-domain structures. This complex structure can interfere with antibody engineering for specific applications, such as the production of protein fusions for multi-specific forms. In addition, the presence of disulfide bonds in antibody molecules usually hinders their use in cells.

[0024] Due to the inherent limitations of antibodies, alternative protein scaffolds have been developed in an attempt to address many or all of these shortcomings. The present disclosure describes a recombinant, non-naturally occurring protein scaffold capable of binding to the extracellular domain of B7-H3, referred to as an affibody. Specifically, the affibody described herein can be used to display a determined helical surface similar to the complementary determining region ("CDR") of an antibody variable region. Affibodies can be assembled into multispecific compounds capable of binding to the extracellular domain of B7-H3 and one or more different targets. Therefore, the affibody described herein can provide functional properties generally associated with antibody molecules. Specifically, although the affibody scaffold is not an immunoglobulin, it is similar in relevant aspects to the scaffold of the variable region of the IgG heavy chain, so that the protein scaffold can display an engineered binding paratope similar to the antibody CDR. Due to this structure, the affibody described herein has ligand binding properties, which can be similar to the binding properties of antigens and antibodies in terms of properties and affinity.

[0025] In one aspect, the present disclosure describes an anti-B7-H3 compound. The anti-B7-H3 compound is or includes an anti-B7-H3 affibody. As used herein, the term "affine" refers to a protein comprising at least one antigen binding site that binds to a specific antigen of interest. The anti-B7-H3 affibody of the present disclosure binds to the extracellular domain of the B7-H3 protein (hereinafter B7-H3). The anti-B7-H3 affibody of the present disclosure is developed from the affibody of SEQ ID NO: 1.

[0026] The anti-B7-H3 affibody of the present disclosure includes the amino acid sequence AEAKYXKEXXXAXXXIXXLPNLXXXQXXAFXXXLXXDPSQSSELXXEAX KLNDSQAPK (SEQ ID NO: 2) or a structurally similar sequence. Each X in SEQ ID NO: 2 is a natural amino acid, a non-natural amino acid, or a modified amino acid, and is not related to the amino acid residue at any other position in the affibody. In one or more embodiments, X at position 6 is Y, N, S, T, D, or A; X at position 9 is L, R, K, W, D, I, N, or Q; X at position 10 is H, A, S, F, I, D, E, Q, T, N, or L; X at position 11 is T, Y, D, A, L, P, I, or N; X at position 13 is I, Y, L, V, T, or F; X at position 14 is Q, Y, L, V, G, F, E, A, M, or S; X at position 15 is V, S, Q, or E; X at position 17 is H, A, V, G, R, I, F, or L; X at position 18 is S, Y, L, G, T, N, M, D, R, W, E, or H; X at position 23 is T or A; X at position 24 is L, K, A, G, R, H, W, V, or E; X at position 25 is D, P, T, N, V, S, H, L, R, A, W, or E; X at position 27 is R, K, T, I, or A; X at position 28 is A, Y, R, N, D, Q, I, H, L, S, or F; X at position 31 is L, K, I, or T; X at position 32 is L, G, Y, R, A, F, V, S, or Q; X at position 32 is A or K; X at position 35 is F, S, V, H, Y, D, E, or K; X at position 36 is N or D; X at position 44 is L or F; X at position 46 is S or P; and X at position 49 is R or K.

[0027] As used herein, a polypeptide (e.g., an affibody) is "structurally similar" to a reference polypeptide (e.g., an anti-B7-H3 affibody comprising SEQ ID NO: 3) if its amino acid sequence has a specified amount of identity compared to the reference polypeptide. The structural similarity of two polypeptides (e.g., a candidate polypeptide and a polypeptide such as SEQ ID NO: 3) can be determined by aligning the residues of the two polypeptides to optimize the number of identical amino acids along the length of their sequences; when aligning, gaps in either or both sequences are allowed to optimize the number of identical amino acids, but the amino acids in each sequence must remain in their correct order. A candidate polypeptide is a polypeptide to be compared to a reference polypeptide (e.g., SEQ ID NO: 3). A candidate polypeptide can be isolated, for example, from an animal or other natural source, or can be produced using recombinant technology, or chemically or enzymatically synthesized.

[0028] The BESTFIT algorithm in the GCG package (version 10.2, Madison WI) can be used to perform paired comparison analysis of amino acid sequences. Alternatively, the Blastp program of the BLAST 2 search algorithm can be used to compare polypeptides, and the BLAST 2 search algorithm is as described by Tatiana et al., (FEMS Microbiol Lett, 174, 247-250 (1999)) and can be obtained on the website of the National Center for Biotechnology Information (NCBI). The default values ​​of all BLAST 2 search parameters can be used, including matrix=BLOSUM62; open gap penalty=11, extension gap penalty=1, gap x_dropoff=50, expectation=10, word length=3, and filter is turned on.

[0029] When comparing two amino acid sequences, structural similarity can be expressed as a percentage "identity" or as a percentage "similarity". "Identity" refers to the presence of identical amino acids. "Similarity" refers to the presence of not only identical amino acids, but also conservative substitutions. Conservative substitutions of amino acids in a polypeptide can be selected from other members of the class to which the amino acid belongs. For example, it is well known in the field of protein biochemistry that amino acids belonging to a grouping of amino acids with a specific size or property (such as charge, hydrophobicity, and hydrophilicity) can replace another amino acid without changing the activity of the protein, particularly in regions of the protein that are not directly related to biological activity. For example, non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Positively charged (basic) amino acids include arginine, lysine, and histidine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Conservative substitutions include, for example, Lys replacing Arg and vice versa to maintain a positive charge; Glu replacing Asp and vice versa to maintain a negative charge; Ser replacing Thr to maintain free -OH; and Gln replacing Asn to maintain free -NH2. Likewise, biologically active analogs of polypeptides are also contemplated, which comprise deletions or additions of one or more consecutive or non-consecutive amino acids that do not eliminate the functional activity of the polypeptide.

[0030] The anti-B7-H3 affibody as described herein may have at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with SEQ ID NO: 2, wherein each X is independently selected from any amino acid. The anti-B7-H3 affibody as described herein may have at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with SEQ ID NO: 2, wherein X at position 6 is Y, N, S, T, D or A; X at position 9 is L, R, K, W, D, I , N or Q; X at position 10 is H, A, S, F, I, D, E, Q, T, N or L; X at position 11 is T, Y, D, A, L, P, I or N; X at position 13 is I, Y, L, V, T or F; X at position 14 is Q, Y, L, V, G, F, E, A, M or S; X at position 15 is V, S, Q or E; X at position 17 is H, A, V, G, R, I , F or L; X at position 18 is S, Y, L, G, T, N, M, D, R, W, E or H; X at position 23 is T or A; X at position 24 is L, K, A, G, R, H, W, V or E; X at position 25 is D, P, T, N, V, S, H, L, R, A, W or E; X at position 27 is R, K, T, I or A; X at position 28 is A, Y, R, N, X at position 31 is L, K, I or T; X at position 32 is L, G, Y, R, A, F, V, S or Q; X at position 32 is A or K; X at position 35 is F, S, V, H, Y, D, E or K; X at position 36 is N or D; X at position 44 is L or F; X at position 46 is S or P; and X at position 49 is R or K.

[0031] An anti-B7-H3 affibody as described herein may have at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of SEQ ID NO:3 to SEQ ID NO:20 or SEQ ID NO:22 to SEQ ID NO:34.

[0032] The anti-B7-H3 affibodies described herein may have at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence similarity to any one of SEQ ID NO:3 to SEQ ID NO:20 or SEQ ID NO:22 to SEQ ID NO:34.

[0033] The present disclosure does not describe SEQ ID NO: 21. Therefore, any SEQ ID NO range described as covering SEQ ID NO: 21 does not include SEQ ID NO: 21. For example, the statement "any one of SEQ ID NO: 2 to SEQ ID NO: 34" refers to any one of SEQ ID NO: 3 to SEQ ID NO: 20 and any one of SEQ ID NO: 22 to SEQ ID NO: 34.

[0034] In one or more embodiments, amino acids in the helical surface region of any one of SEQ ID NO: 2 to SEQ ID NO: 34 may be mutated. The mutation may include substitution of one or more amino acid residues with a different amino acid residue, deletion of one or more amino acid residues, addition of one or more amino acid residues, or any combination thereof for any one of SEQ ID NO: 2 to SEQ ID NO: 34.

[0035] For example, in one or more embodiments, one or more mutations may be present in amino acid residues 6-18 of any one of SEQ ID NO:2 to SEQ ID NO:34. In some of those embodiments, residue 6 of any one of SEQ ID NO:2 to SEQ ID NO:34 may be mutated. In one or more embodiments, one or more mutations may be present in amino acid residues 9-11 of any one of SEQ ID NO:2 to SEQ ID NO:34. In one or more embodiments, one or more mutations may be present in amino acid residues 13-15 of any one of SEQ ID NO:2 to SEQ ID NO:34. In one or more embodiments, amino acid residues 17 and / or 18 of any one of SEQ ID NO:2 to SEQ ID NO:34 may be mutated. In one or more embodiments, one or more mutations may be present in amino acid residues 24-36 of SEQ ID NO:19. In some of those embodiments, residues 24 and / or 25 of any one of SEQ ID NO:2 to SEQ ID NO:34 may be mutated. In one or more embodiments, residues 27 and / or 28 of any one of SEQ ID NO:2 to SEQ ID NO:34 may be mutated. In one or more embodiments, one or more mutations may be present in amino acid residues 31-33 of any one of SEQ ID NO:2 to SEQ ID NO:34. In one or more embodiments, residues 35 and / or 36 of any one of SEQ ID NO:2 to SEQ ID NO:34 may be mutated. In one or more embodiments, one or more mutations may be present in any of the amino acid residue regions described herein.

[0036] In one or more embodiments, one or more amino acid mutations may be present outside the helical surface region of any one of SEQ ID NO: 2 to SEQ ID NO: 34. For example, in one or more embodiments, one or more mutations may be present in amino acid residues 1-5 of any one of SEQ ID NO: 2 to SEQ ID NO: 34. In one or more embodiments, one or more mutations may be present in amino acid residues 19-23 of any one of SEQ ID NO: 2 to SEQ ID NO: 34. In one or more embodiments, one or more mutations may be present in amino acid residues 37-58 of any one of SEQ ID NO: 2 to SEQ ID NO: 34.

[0037] In one or more embodiments, one or more mutations may be present in one or more helical surface regions of any one of SEQ ID NO:2 to SEQ ID NO:34 and one or more mutations may be present outside of the helical surface regions of any one of SEQ ID NO:2 to SEQ ID NO:34.

[0038] Table 1 shows the amino acid sequence of the parent affibody from which the anti-B7-H3 affibody of the present invention is derived (SEQ ID NO: 1); the general consensus sequence (SEQ ID NO: 2); the second consensus sequence (SEQ ID NO: 3) of SEQ ID NO: 4 to SEQ ID NO: 18. Table 1 also shows exemplary identities of X of the general consensus sequence (SEQ ID NO: 2) and exemplary mutations of any one of SEQ ID NO: 4 or SEQ ID NO: 3 to SEQ ID NO: 34. In one or more embodiments, the anti-B7-H3 affibody scaffold of the present disclosure includes any one of SEQ ID NO: 2 to SEQ ID NO: 34 with any combination of the exemplary possible mutations or possible identities of X shown in Table 1.

[0039] Table 1.

[0040]

[0041]

[0042] Variants of the disclosed sequences also include fragments or full-length Affibodies that contain substitutions, deletions or insertions in the protein backbone, but still retain at least about 70% homology to the original Affibodies in the corresponding portion. Greater homology deviations are permitted if similar amino acids (i.e., conservative amino acid substitutions) are not considered changes in the sequence. Examples of conservative substitutions involve amino acids with identical or similar properties. Illustrative conservative amino acid substitutions include the following changes: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartic acid to glutamic acid or asparagine; cysteine ​​to serine; glutamine to asparagine or glutamic acid; glutamic acid to aspartic acid or glutamine; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine or glutamic acid; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine or alanine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; valine to isoleucine or leucine.

[0043] In one or more embodiments, the anti-B7-H3 affibody of the present disclosure may include additional sequences, such as amino acids added to the C-terminus or N-terminus of the anti-B7-H3 affibody. For example, such modifications may facilitate purification by capture on a column, the use of an antibody, or facilitate recovery when recombinantly expressed in a microorganism. Such tags include, for example, histidine-rich tags that enable protein purification on a nickel column and / or leader sequences that can transport recombinantly expressed anti-B7-H3 affibody to the membrane of a cell in which the affibody is recombinantly expressed. Such gene modification techniques and suitable additional sequences are well known in the field of molecular biology. In one or more embodiments, the C-terminus and / or N-terminus modifications may be cut off from the anti-B7-H3 affibody before being incorporated into, for example, a pharmaceutical composition. In other embodiments, it may be necessary to retain the C-terminus or N-terminus modifications for a given application, for example to facilitate fixation to a matrix.

[0044] In one or more embodiments, the anti-B7-H3 affibodies described herein may also include an N-terminal or C-terminal functional group other than a carboxylic acid or a free amine. For example, the C-terminus, the N-terminus, or both of the affibodies may be acylated, such as acetylated. In one or more embodiments, the functional group may include a polyol (e.g., polyethylene glycol).

[0045] In one or more embodiments, the anti-B7-H3 affibodies described herein may include post-translational modifications to one or more amino acids. Examples of post-translational modifications include, but are not limited to, acetylation, methylation, glycosylation, phosphorylation, prenylation, sulfonation, palmitoylation, hydroxylation, nitration, myristoylation, formylation, or citrullination. Post-translational modifications may be incorporated specifically or non-specifically by methods known in the biological art.

[0046] In one or more embodiments, the anti-B7-H3 affibody can be recombinantly produced in a suitable host cell and then purified. Methods for recombinant production and purification of proteins are well known in the art.

[0047] In one or more embodiments, the anti-B7-H3 affibodies of the present disclosure can be produced using solid phase peptide synthesis. In this production method, the anti-B7-H3 affibodies can be synthesized as a complete polypeptide or as multiple polypeptide fragments, which can be linked using native chemical ligation, expressed protein ligation, Staudinger ligation, or Ser / Thr ligation. Solid phase peptide synthesis methods and ligation techniques are well known in the art.

[0048] In another aspect, the present disclosure describes polynucleotides encoding any anti-B7-H3 affibody described herein, as well as the complement of such polynucleotide sequences. Given the amino acid sequence of any anti-B7-H3 affibody described herein, one of ordinary skill in the art can determine the full range of polynucleotides encoding the amino acid sequence using conventional, customary methods.

[0049] The anti-B7-H3 affibodies disclosed herein can be engineered using a variety of techniques and assays. For example, magnetic activated cell sorting (MACS) and fluorescence activated cell sorting (FACS) can be used to select affibodies of interest that bind to B7-H3 in a yeast display model.

[0050] The following describes a scheme for engineering at least a portion of the anti-B7-H3 affibodies disclosed herein (see Examples 1 and 2 for additional details). An affibody scaffold library comprising an affibody amino acid sequence derived from SEQ ID NO: 1 was used to discover binders of B7-H3 via yeast display, magnetic activated cell sorting, and fluorescence activated cell sorting. The library (0.0 affibody population, also referred to as the library) was subjected to three MACS selections (obtaining 0.1, 0.2, and 0.3 affibody populations) using the recombinant human B7-H3 extracellular domain immobilized on magnetic beads, followed by a single FACS selection using 50 nM of the same recombinant B7-H3 protein, and gated to select affibodies with medium affinity, yielding a 0.4 population. DNA was isolated from the entire 0.4 affibody population, randomly mutated via error-prone PCR, and electroporated back into yeast. The mutant untreated population was subjected to MACS selection (obtaining the 1.1 Affibody population), followed by monovalent MACS sorting with 100 nM recombinant human B7-H3 (obtaining the 1.2 Affibody population). The 1.2 Affibody population was then further enriched with two FACS selections with increasing stringency using detergent-dissolved MS1-B7-H3 lysate (using estimated B7-H3 lysate concentrations of 50 nM and 1 nM) (obtaining the 1.3 and 1.4 Affibody populations). Yeast was cultured and re-induced between each selection. The 1.4 Affibody population continued with another round of selection to sort for proteases and thermostable Affibodies with B7-H3 binding, yielding population 1.5 ( FIG. 2 ).

[0051] Figure 1A is a graph showing the theoretical diversity of various sorted Affibody populations (0.4 is the 0.4 population). Populations 0.2, 0.3, and 1.2 exhibit specific binding to B7-H3 but not to the negative control. The higher the theoretical diversity, the more cells are collected for that parameter (e.g., control, negative, or B7-H3 binder). Population 1.1 has the highest theoretical diversity of cells that bind B7-H3. Figure 1BFlow cytometric analysis (FACS) of 10,000 random variants of the 0.4 population. This yielded moderate affinity binders to recombinant B7-H3. Figure 1C is a flow cytometric analysis of the enriched 1.4 population, which consists of Figure 1B A 0.4 population of mutations (shown in grey boxes) and subsequent sorting were generated as described previously. Figure 1C Cell lysate was labeled with approximately 1 nM biotin-B7-H3, streptavidin-AF647 and chicken anti-c-Myc-FITC. This produced a high affinity binder to cellular B7-H3. Figure 1B and Figure 1C The box in shows the population collected during FACS sorting. The collected cells express the full-length Affibody and bind to B7-H3. Figure 1B A rectangle is drawn in to select binders, since the majority of the population is non-binding. Figure 1C In , a diagonal polygon was drawn to be more stringent and collect the top-ranked binders with higher affinity.

[0052] Individual colonies of the affimer population were randomly selected and subjected to Sanger sequencing at two selection points (see Figure 3 ): (1) After the first FACS sorting (fourth sorting overall; resulting in a 0.4 population), and after additional selections after error-prone PCR (two MACS selections and two FACS lysate selections; resulting in a 1.4 population). After protease and thermostable B7-H3 binding sorting (producing a 1.5 population), the affibody variants were subjected to a third Sanger sequencing. The sequencing results of the affibody are shown in Figure 3 wherein (ABY025 is the Affibody sequence from which the anti-B7-H3 Affibody is derived = SEQ ID NO: 1; 0.4.1 = SEQ ID NO: 4; 0.4.2 = SEQ ID NO: 5; 0.4.3 = SEQ ID NO: 6; 0.4.4 = SEQ ID NO: 7; 0.4.5 = SEQ ID NO: 8; 0.4.6 = SEQ ID NO: 9; 0.4.7 = SEQ ID NO: 10; 1.4.1 = SEQ ID NO: 11; 1.4.2 = SEQ ID NO: 12; 1.4.3 = SEQ ID NO: 13; 1.4.4 = SEQ ID NO: 14; 1.4.5 = SEQ ID NO: 15; 1.4.6 = SEQ ID NO: 16; 1.4.7 = SEQ ID NO: 17; 1.4.8 = SEQ ID NO: 18; 1.5.1 = SEQ ID NO: 19; 1.5.2 = SEQ ID NO20).

[0053] The 1.5 Affibody population was further engineered for affinity specificity, specificity, and stability maturation (see Example 2 for additional details). DNA was isolated from the 1.5 yeast population and random mutagenesis was performed via error-prone polymerase chain reaction (PCR) of the variable regions of the Affibody. The DNA was electroporated back into yeast for display and further sorted using the following sorting schemes: (1) Lysate MACS sorting with 1 pmol B7-H3+ lysate (affinity sorting); (2) Affinity sorting (strict K d FACS sorting); (3) specificity sorting (multi-target MACS depletion sorting); and (4) stability sorting (thermolysin FACS sorting at 55°C). After each sorting, the population was deeply sequenced.

[0054] The frequency of each sequence in each sorting (e.g., affinity, avidity, specificity, and stability) and their subsequent enrichment were determined. If the read count was 0, a read count of 1 was assigned. The z scores for affinity, specificity, stability, and final frequency of the top-ranked variants were determined, and the final conditional weighted average z scores were calculated (see Example 2). The best performers were selected based on the highest scores. Figure 5 The sequences of the top performers in the 1.5.1 population after all sortings were completed are shown.

[0055] Figure 6 The z scores for affinity, specificity, stability, and final frequency are shown, as well as the conditionally weighted average z scores of the top-ranked variants. Values ​​greater than 1 indicate enrichment, while values ​​less than 1 indicate depletion. Figure 6 In the Figure 1, the affinity color bar ranges from M–M+2SD enrichment, while specificity and stability are shown as 1–M+2SD because the mean (M) is slightly less than 1. On the bar graphs, z-scores are shown from 1-10 (i.e., if the z-score is 10 or higher, the bar spans the entire length of the graph).

[0056] Figure 7 is a graph showing the relative frequency of a particular variant (each line) after each sort (affinity, avidity, specificity and stability). The ideal variant should be represented by a straight line with a high relative frequency in all sorts.

[0057] In addition to the anti-B7-H3 affibody, in one or more embodiments, the anti-B7-H3 compound may include a first functional component operably linked to the anti-B7-H3 affibody. In one or more embodiments, the first functional component may include a targeting component. In one or more embodiments, the first functional component may include an imaging component. In one or more embodiments, the first functional component may include an enzyme. In one or more embodiments, the first functional component may include a small molecule drug, a pharmacologically active derivative thereof, or an activatable inactive form of a drug (e.g., a prodrug).

[0058] In one or more embodiments, the first functional component includes a targeting component. In embodiments where the first functional component includes a targeting component, the anti-B7-H3 compound can be an immunotherapy compound. Immunotherapeutic compounds can provide personalized treatments that activate or suppress the immune system to amplify or weaken the immune response, and are rapidly developing for the treatment of various forms of cancer. Immunotherapies for cancer (such as chimeric antigen receptor (CAR)-T cells, CAR-natural killer (NK) cells, PD-1 and PD-L1 inhibitors) are intended to help the subject's immune system fight cancer.

[0059] In one or more embodiments, the targeting component can bind to the B7-H3 display cell and recruit effector cells to the B7-H3 display cell. The types of effector cells include but are not limited to natural killer (NK) cells, B cells or T cells. The targeting component can bind to the surface protein displayed on the effector cell. Non-limiting examples of surface proteins displayed on NK cells include CD16, PD-1, NKp30, NKp40, NKp44, NKp46, NKG2C or KIR. Non-limiting examples of surface proteins displayed on B cells include CD4, CD8 or VLA-4. Non-limiting examples of surface proteins displayed on T cells include (LFA)-1, CD2, CD4 or CD8.

[0060] In one or more embodiments, the targeting component may include an antibody or fragment thereof, an affibody, a peptide, a protein, or a small molecule.

[0061] In one or more embodiments, the first functional component comprises an imaging component. In embodiments where the first functional component comprises an imaging component, the anti-B7-H3 compound can be used as a diagnostic tool to detect B7-H3 positive tumors.

[0062] The imaging assembly can be any assembly that can produce a detectable signal. Exemplary types of imaging assemblies include, but are not limited to, colorimetric labels, fluorescent labels, radioactive labels, magnetic labels, or enzyme labels. Depending on the type of imaging assembly, various methods can be used to detect the imaging assembly. Exemplary detection methods include magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), ultrasound, photoacoustic imaging, fluorescence microscopy, total internal reflection fluorescence (TIRF) microscopy, or stimulated emission depletion (STRED) nanoscopy. Imaging techniques can be performed in vivo or in vitro.

[0063] In one or more embodiments, the first functional component may include an enzyme. In one or more embodiments, the enzyme may modify one or more of the surface proteins displayed on the B7-H3 displaying cells to which the anti-B7-H3 Affibody binds. Examples of enzymes that modify surface proteins include, but are not limited to, proteases, lipases, or sortases, such as sortase A.

[0064] For example, to analyze the modularity of Affibodies, Affibody 1.5.2 (SEQ ID NO: 20) was genetically linked to the sortase A protease via a 15 amino acid glycine-rich linker (SEQ ID NO: 35) at the C-terminus of the Affibody, i.e. Affibody 1.5.2-L 15 -SrtA fusion (see Example 1). Modularity was assessed by retention of the B7-H3 binding affinity of the Affimer in the presence of a glycine-linked sortase A enzyme. Although the binding affinity of Affimer 1.5.2 alone was not assessed, Affimer 1.5.2-L 15 -K of SrtA d 4.9 nM (4.0–5.9 nM), exhibiting low nanomolar affinity in the presence of linked sortase A ( Figure 4 ).

[0065] In one or more embodiments, the first functional component may include a small molecule drug. As used herein, the term "drug" is used to refer to a pharmacologically active substance or an activatable inactive form of a pharmacologically active substance (e.g., a prodrug). In embodiments where the first functional component includes a small molecule drug, the anti-B7-H3 compound may be a chemotherapeutic compound. In one or more embodiments, the chemotherapeutic compound may include one or more radioactive isotopes. In embodiments where the chemotherapeutic compound includes one or more radioactive isotopes, the anti-B7-H3 compound may be used for radioisotope therapy (radionuclide therapy). Examples of suitable isotopes include iodine-131, iridium-192, strontium-89, samarium-153, rhenium-186, boron-10, phosphorus-32, or radium-223. The anti-B7-H3 affibody allows the small molecule drug to be localized to B7-H3 display cells (e.g., tumor cells), thereby delivering the chemotherapeutic compound to tumor cells expressing B7-H3. In this manner, the chemotherapeutic compound can be systemically administered to a subject and still have increased local activity and reduced systemic side effects compared to administering the drug systemically without being a component of the anti-B7-H3 compound.

[0066] In one or more embodiments, the anti-B7-H3 compound may include additional functional components in addition to the first functional component and the anti-B7-H3 affibody. For example, the anti-B7-H3 compound may include a second functional component, a third functional component, a fourth functional component, a fifth functional component, a sixth functional component, or a seventh functional component. Each functional component may include an anti-B7-H3 affibody or include an imaging component, an enzyme, a small molecule drug, or a targeting component (all of which have been previously described herein), regardless of the identity of any other component in the anti-B7-H3 compound.

[0067] In some embodiments where the anti-B7-H3 compound includes at least one functional component, the anti-B7-H3 affibody and the functional component are operably connected. As used herein, the term "operably connected" refers to a direct or indirect covalent connection between an anti-B7-H3 affibody and any additional one or more functional components of the anti-B7-H3 compound. Therefore, two operably connected functional components or a functional component and an anti-B7-H3 affibody can be directly covalently coupled to another. On the contrary, two operably connected functional components or a functional component operably connected to an anti-B7-H3 affibody can be connected by covalently connecting to an intermediate component (e.g., a flanking sequence or a joint). For example, in an embodiment where the anti-B7-H3 compound includes two functional components, the first functional component and the second functional component can be directly connected to the anti-B7-H3 affibody, respectively; or the first functional component can be directly connected to the anti-B7-H3 affibody and the second functional component is directly connected to the first functional component.

[0068] The anti-B7-H3 affibody and the first functional component can be operably connected by one or more joints. As used herein, the term "joint" refers to any bond, small molecule, peptide sequence or other medium that physically connects the functional components of the anti-B7-H3 compound. The joint can be susceptible to or substantially resist acid-induced cleavage, light-induced cleavage, peptidase-induced cleavage, esterase-induced cleavage and / or disulfide bond cleavage under the condition that the first functional component (or other functional component) and / or the anti-B7-H3 affibody remain active. The joint is classified according to the presence of one or more chemical motifs, for example, including disulfide groups, hydrazines or peptides (cleavable) or thioester groups (non-cleavable). As known in the art, joints also include charged joints and hydrophilic forms thereof.

[0069] Suitable linkers for connecting the anti-B7-H3 affibody and the first functional component of the anti-B7-H3 compound of the present invention include natural linkers, empirical linkers, or a combination of natural linkers and / or empirical linkers. Natural linkers are derived from the amino acid linker sequence of the multi-domain protein, which naturally occurs between protein domains. The properties of the natural linker (e.g., length, hydrophobicity, amino acid residues and / or secondary structure) can be used to confer the desired properties to the multi-domain compound including the natural linker connecting the anti-B7-H3 compound components of the present invention.

[0070] Research on the joints in natural multi-domain proteins has led to the generation of many empirical joints with various sequences and conformations for constructing recombinant fusion proteins. Empirical joints are generally divided into three types: flexible joints, rigid joints and cleavable joints. Flexible joints can provide a certain degree of movement or interaction at the connected components. Flexible joints generally include small non-polar (e.g., Gly) or polar (e.g., Ser or Thr) amino acids that provide flexibility and allow the mobility of the connected components. An example of a flexible joint that can be used to connect the first functional component of the anti-B7-H3 affibody and the anti-B7-H3 compound of the present invention is SEQ ID NO: 35. Rigid joints can successfully maintain a fixed distance between the first functional component of the anti-B7-H3 compound and the anti-B7-H3 affibody to maintain their independent functions, which can provide effective separation of the first functional component and the anti-B7-H3 affibody and / or fully reduce the interference between the first functional component and the anti-B7-H3 affibody. Cleavable joints allow people to control the release of the first functional component and / or the anti-B7-H3 affibody in vivo. By utilizing unique in vivo processes, cleavable linkers can be cleaved under specific conditions, such as in the presence of a reducing agent or a protease. This type of linker can reduce steric hindrance, improve biological activity, and / or enable independent action / metabolism of the first functional component and / or the anti-B7-H3 affibody after linker cleavage.

[0071] Exemplary suitable linker sequences include the amino acid sequences of SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, and SEQ ID NO:47.

[0072] In one or more embodiments, a natural linker or an empirical linker is covalently attached to the anti-B7-H3 Affibody, the first functional component, or both using bioconjugation chemistry. Bioconjugation chemistry is well known in the art and includes, but is not limited to, NHS-ester linkage, isocyanate linkage, isothiocyanate linkage, benzoyl fluoride linkage, maleimide conjugation, iodoacetamide conjugation, 2-thiopyridine disulfide exchange, 3-arylpropyne nitrile conjugation, diazonium salt conjugation, 4-phenyl-3H-1,2,4-triazole-3,5(4H)-dione conjugation, and Mannich linkage.

[0073] In one or more embodiments, the natural linker or empirical linker, the first functional component, the anti-B7-H3 affibody or a combination thereof may include one or more non-natural amino acids that allow bioorthogonal conjugation reactions. As used herein, "bioorthogonal conjugation" refers to a conjugation reaction using one or more non-natural amino acids or modified amino acids as starting reagents. Examples of bioorthogonal conjugation reactions include, but are not limited to, Staudinger ligation, copper-catalyzed azide-alkyne cycloaddition, strain-promoted [3+2] cycloaddition, tetrazine ligation, metal-catalyzed coupling reaction, or oxime-hydrazone ligation. Examples of non-natural amino acids include, but are not limited to, azidohomoalanine, 2-homopropargylglycine, 3-homoallylglycine, 4-p-acetyl-Phe, 5-p-azido-Phe, 3-(6-acetylnaphthalen-2-ylamino)-2-aminopropionic acid, N ε -(cyclooct-2-yn-1-yloxy)carbonyl)L-lysine, N ε -2-Azidoethoxycarbonyl-L-lysine, N ε - p-azidobenzyloxycarbonyllysine, propargyl-L-lysine or trans-cyclooct-2-enelysine. Such amino acids may be incorporated into any position of the anti-B7-H3 affibody of the present disclosure or any position on any functional component.

[0074] In one or more embodiments, the linker is derived from a small molecule, such as a polymer. Exemplary polymer linkers include, but are not limited to, polyethylene glycol, poly(N-isopropylacrylamide) and (N,N'-dimethylacrylamide)-co-4-phenylazophenylacrylate. Small molecule linkers typically include one or more reactive handles that enable conjugation to the anti-B7-H3 affibody, domain, or both. In one or more embodiments, the reactive handles allow for bioconjugation or bioorthogonal conjugation. In one or more embodiments, the reactive handles allow for any organic reaction compatible with conjugating the linker to the anti-B7-H3 affibody or the first functional component.

[0075] The linker can be conjugated to any amino acid position of the anti-B7-H3 affinity body. For example, the linker can be conjugated to the N-terminus, the C-terminus, or any amino acid therebetween.

[0076] In embodiments where the anti-B7-H3 compound includes more than one functional component, the additional functional components can be operably linked to each other and / or to the anti-B7-H3 affibody using one or more of the linkers disclosed herein.

[0077] In some embodiments where the anti-B7-H3 compound comprises an anti-B7-H3 affibody and one or more functional components operably linked via a peptide linker, the anti-B7-H3 compound can be produced by expression in a host cell using methods known in the art. In some embodiments where the anti-B7-H3 compound comprises an anti-B7-H3 affibody and one or more functional components operably linked via a peptide linker, the anti-B7-H3 compound can be produced using solid phase peptide synthesis using methods known in the art.

[0078] In another aspect, the present disclosure describes an isolated nucleic acid sequence encoding the amino acid sequence of any embodiment of the anti-B7-H3 compound or any component polypeptide fragment thereof described herein. Given the amino acid sequence of any polypeptide, one of ordinary skill in the art can determine the full range of the polynucleotide encoding the amino acid sequence using conventional, customary methods.

[0079] In another aspect, the present disclosure describes a host cell comprising any of the isolated nucleic acid sequences, anti-B7-H3 compounds and / or anti-B7-H3 affibodies described herein.

[0080] The nucleic acid constructs disclosed herein can be introduced into host cells to be altered, thereby allowing anti-B7-H3 compounds and / or anti-B7-H3 affibodies to be expressed intracellularly, thereby generating genetically engineered cells. Various methods are known in the art and are suitable for introducing nucleic acids into cells, including viral and non-viral mediated techniques. Examples of typical non-viral mediated techniques include, but are not limited to, electroporation, calcium phosphate mediated transfer, nuclear transfection, sonoporation, heat shock, magnetofection, liposome mediated transfer, microinjection, microparticle mediated transfer (e.g., nanoparticles), cationic polymer mediated transfer (e.g., DEAE-dextran, polyethyleneimine, polyethylene glycol (PEG), etc.), or cell fusion. Other transfection methods include proprietary transfection reagents such as LIPOFECTAMINE (Thermo Fisher Scientific, Inc., Waltham, MA), HILYMAX (Dojindo Molecular Technologies, Inc., Rockville, MD), FUGENE (Promega Corp., Madison, WI), JETPEI (Polyplus Transfection, Illkirch, France), EFFECTENE (Qiagen, Hilden, Germany), and DreamFect (OZ Biosciences, Inc USA, San Diego, CA).

[0081] The nucleic acid constructs described herein can be introduced into host cells to be changed, thereby allowing the anti-B7-H3 compounds and / or anti-B7-H3 affibodies encoded by nucleic acids to be expressed in cells. A variety of host cells are known in the art and are suitable for protein expression. Examples of typical cells for transfection and protein expression include, but are not limited to, bacterial cells, eukaryotic cells, yeast cells, insect cells or plant cells, such as Escherichia coli (E.coli), Bacillus (Bacillus), Streptomyces (Streptomyces), Pichia pastoris (Pichia pastoris), Salmonella typhimurium (Salmonellatyphimurium), Drosophila S2 (Drosophila S2), Spodoptera SJ9 (Spodoptera SJ9), CHO, COS (e.g., COS-7), 3T3-F442A, HeLa, HUVEC, HUAEC, NIH 3T3, Jurkat, 293, 293H or 293F.

[0082] In another aspect, the present disclosure provides a pharmaceutical composition comprising one or more anti-B7-H3 compounds described herein (including anti-B7-H3 compounds comprising anti-B7-H3 affibodies and not comprising additional functional components), formulated together with a pharmaceutically acceptable carrier. Such compositions may include one anti-B7-H3 compound or, for example, a combination of two or more different anti-B7-H3 compounds.

[0083] As used herein, "pharmaceutically acceptable" refers to a material that is not biologically or otherwise undesirable, e.g., a material that can be administered to an individual along with an anti-B7-H3 compound without causing any undesirable biological effect or interacting in a deleterious manner with any other component of the pharmaceutical composition in which it is contained.

[0084] The pharmaceutical composition may include one or more pharmaceutically acceptable salts. Examples of such salts include acid addition salts and base addition salts. The pharmaceutical composition may also include or alternatively include a pharmaceutically acceptable antioxidant. Those skilled in the art generally know and understand how to apply the use of pharmaceutically acceptable salts and / or pharmaceutically acceptable antioxidants.

[0085] Pharmaceutical compositions can be formulated with pharmaceutically acceptable carriers. As used herein, the term "carrier" includes any solvent, dispersion medium, vehicle, coating, diluent, antibacterial and / or antifungal agent, isotonic agent, absorption delay agent, buffer, carrier solution, suspending agent, hydrogel, colloid, adjuvant, stabilizer, protein carrier, biological carrier compound, etc. Non-limiting examples of solvents include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.), vegetable oils (such as olive oil) or injectable organic esters (such as ethyl oleate) or combinations thereof. Non-limiting examples of protein carriers include keyhole limpet hemocyanin (keyhole limpet hemocyanin, KLH), bovine serum albumin (BSA), ovalbumin, etc. Non-limiting examples of biological compounds that can be used as carriers include glycosaminoglycans, proteoglycans or albumin. Carriers can include organic solvents (such as dimethyl sulfoxide), synthetic compounds or synthetic polymers (such as polyalkylene glycols). Ovalbumin, human serum albumin, other proteins, polyethylene glycol, etc. can be used as carriers. The use of such media and / or agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active ingredient (i.e., anti-B7-H3 compound), they can be considered for use in therapeutic compositions. Supplementary active ingredients can also be incorporated into the composition.

[0086] The pharmaceutical composition may also include or alternatively may include one or more adjuvants, such as preservatives, wetting agents, emulsifiers and / or dispersants. In one or more embodiments, the pharmaceutical composition may include antibacterial and / or antifungal agents, such as parabens, chlorobutanol, phenol sorbic acid, etc. Including isotonic agents in the composition, such as sugar, sodium chloride or polyols (such as mannitol, sorbitol, etc.) may also be desirable. In addition, the extended absorption of injectable drug forms may be provided by including a medicament (such as aluminum monostearate or gelatin) that delays absorption.

[0087] Therefore, the anti-B7-H3 compounds of the present disclosure can be formulated into pharmaceutical compositions. Pharmaceutical compositions can be formulated into various forms adapted to preferred routes of administration. Therefore, the compositions can be administered via known routes, including, for example, oral, parenteral (e.g., intradermal, transdermal, subcutaneous, intramuscular, intravenous, intraperitoneal, etc.) or topical (e.g., intranasal, intrapulmonary, intramammary, intravaginal, intrauterine, intradermal, transdermal, rectal, etc.). The pharmaceutical composition can be applied to mucosal surfaces, such as by application to, for example, nasal mucosa or respiratory mucosa (e.g., by spray or aerosol). The composition can also be administered via sustained release or delayed release.

[0088] The preparation can be conveniently presented in unit doses and can be prepared by methods known in the pharmaceutical art. The method of preparing a composition with a pharmaceutically acceptable carrier includes the step of combining the anti-B7-H3 compound with a carrier constituting one or more auxiliary components. Generally, the preparation can be prepared by uniformly and / or closely combining the active ingredient with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product into the desired preparation.

[0089] To prepare a pharmaceutical composition comprising an anti-B7-H3 compound of the present disclosure, the anti-B7-H3 compound can be mixed with a pharmaceutically acceptable carrier or excipient. The preparation of therapeutic and diagnostic agents can be prepared by mixing with a physiologically acceptable carrier, excipient or stabilizer in the form of, for example, a lyophilized powder, slurry, aqueous solution, lotion or suspension.

[0090] Therefore, the anti-B7-H3 compounds of the present disclosure can be provided in any suitable form, including but not limited to solutions, suspensions, emulsions, sprays, aerosols or any mixtures thereof. The composition can be formulated for delivery with any pharmaceutically acceptable excipient, carrier or vehicle.

[0091] Nasal spray formulations include a purified aqueous solution of active ingredient with a preservative and an isotonic agent. Such formulations are preferably adjusted to a pH and isotonic state compatible with the nasal mucosa. Rectal or vaginal formulations may be presented as suppositories with suitable carriers such as cocoa butter, hydrogenated fats or hydrogenated fatty carboxylic acids. Ophthalmic formulations are prepared by a method similar to nasal sprays, except that pH and isotonic factors are preferably adjusted to match the pH and isotonic factors of the eye.

[0092] Topical preparations include anti-B7-H3 compounds dissolved or suspended in one or more media (such as mineral oil, petroleum, polyhydroxy alcohols or other matrices for topical pharmaceutical preparations). For example, topical preparations may include creams, ointments, pastes, lotions, powders, solids, aerosolized foams or gels. Topical preparations may contain penetration enhancers to increase the bioavailability of the active ingredient. Topical preparations may contain preservatives and / or emulsifiers. Topical preparations may be provided in the form of transdermal patches or bandages, wherein the preparation is incorporated into gauze or other structures and contacted with the skin. The preparation may further include one or more additives, including, for example, adjuvants, skin penetration enhancers, colorants, spices, flavorings, moisturizers, thickeners, etc.

[0093] The formulations of the present disclosure suitable for oral administration can be presented as discrete units (such as tablets, lozenges, capsules, troches, wafers or cachets), each discrete unit containing a predetermined amount of active ingredients as a powder or granules, as liposomes, or as a solution or suspension in an aqueous liquid or non-aqueous liquid (such as a syrup, elixir, emulsion or potion). Tablets, lozenges, pills, capsules, etc. may also contain one or more of the following: a binder such as gum tragacanth, gum arabic, corn starch or gelatin; an excipient such as calcium hydrogen phosphate; a disintegrant such as corn starch, potato starch, alginic acid, etc.; a lubricant such as magnesium stearate; a sweetener such as sucrose, fructose, lactose or aspartame; or a natural or artificial flavoring. When the unit dosage form is a capsule, it may further contain a liquid carrier such as a vegetable oil or polyethylene glycol. Various other materials may be presented as a coating or otherwise change the physical form of the solid unit dosage form. For example, tablets, pills or capsules can be coated with gelatin, wax, shellac, sugar and / or the like. Syrups or elixirs can include one or more sweeteners, preservatives (such as methylparaben or propylparaben), agents that delay sugar crystallization, agents that increase the solubility of any other ingredients (for example, polyols, such as glycerol or sorbitol), dyes and / or flavorings. The material used to prepare any unit dosage form is substantially nontoxic in the amount used. Active ingredient can be incorporated into a preparation or device in the form of a preparation that can be designed for sustained release or that is not designed for sustained release.

[0094] Preparations suitable for parenteral administration may include a sterile aqueous preparation of the active ingredient, or a dispersion of a sterile powder of the active ingredient, which is preferably isotonic with the blood of the recipient. Parenteral administration (e.g., by intravenous infusion) of the anti-B7-H3 compound of the present disclosure or a pharmaceutical composition containing it is a form of administration. Isotonic agents that may be included in the liquid preparation include sugars, buffers and / or sodium chloride. The solution of the active ingredient can be prepared in water, optionally mixed with a non-toxic surfactant. The dispersion of the active ingredient can be prepared in water, ethanol, a polyol (such as glycerol, propylene glycol, liquid polyethylene glycol, etc.), a vegetable oil, a glyceride, or any mixture thereof.

[0095] In another aspect, the present disclosure provides imaging methods and methods for treating, ameliorating, detecting, diagnosing or monitoring a disease as described herein or a symptom or clinical sign thereof in a patient by administering a therapeutically effective amount of an anti-B7-H3 compound as described herein and / or a pharmaceutical composition comprising one or more anti-B7-H3 compounds as described herein. As used herein, the term "treatment" and its variants refer to reducing, limiting progression, improving or eliminating symptoms or clinical signs associated with a condition to any extent. "Symptoms" refer to any subjective evidence of a disease or a patient's condition; "signs" or "clinical signs" refer to objective physical findings associated with a particular condition that can be found by a person other than the patient. "Treatment" can be therapeutic or preventive. "Treatment" and its variants refer to treatment that improves one or more existing symptoms or clinical signs associated with a condition. "Preventive" and its variants refer to treatment that limits the development and / or appearance of symptoms or clinical signs of a condition to any extent. Typically, "therapeutic" treatment begins after the condition manifests in the subject, while "preventive" treatment begins before the condition manifests in the subject. Preventive treatment can be administered to subjects at risk of the disease. "At risk" means that a subject may or may not actually have the risk. For example, in the case of a non-infectious condition, a subject "at risk of developing a particular condition" is a subject who has one or more signs of an increased risk of having or developing the particular condition, compared to an individual who lacks the one or more signs, regardless of whether the subject exhibits any symptoms or clinical signs of having or developing the condition.

[0096] Thus, in one or more embodiments, the subject to be treated includes a subject suffering from cancer or at risk of suffering from cancer. Typically, the method comprises administering to the subject an effective amount of an anti-B7-H3 compound. As used herein, the term "cancer" refers to a group of diseases characterized by abnormal and uncontrolled cell proliferation starting from one site (primary site) that may invade and spread to other sites (secondary sites, metastasis) (which distinguishes cancer (malignant tumors) from benign tumors). As used herein, "neoplasm" (and grammatical variants thereof) refers to new and abnormal growth of tissue, which may be benign or cancerous. In related aspects, a tumor represents a neoplastic disease or condition, including but not limited to various cancers. For example, such cancers may include prostate cancer, pancreatic cancer, bile duct cancer, colon cancer, rectal cancer, liver cancer, kidney cancer, lung cancer, testicular cancer, breast cancer, ovarian cancer, brain cancer and head and neck cancer, melanoma, sarcoma, multiple myeloma, leukemia, lymphoma, and the like.

[0097] The amount of the anti-B7-H3 compound may vary depending on various factors, including, but not limited to, the anti-B7-H3 compound used, the weight, physical condition and / or age of the subject, and / or the route of administration. Thus, the absolute weight of the anti-B7-H3 compound contained in a given unit dosage form may vary widely and depend on factors such as the species, age, weight and physical condition of the subject, and / or the method of administration. Thus, it is impractical to generally state an amount that constitutes an amount of anti-B7 compound that is effective for all possible applications. However, one of ordinary skill in the art can readily determine an appropriate amount with due consideration of such factors.

[0098] In one or more embodiments, the method may include administering an anti-B7-H3 compound in an amount sufficient to provide a dose of, for example, about 100 ng / kg to about 50 mg / kg to the subject, although in some embodiments, the method may be performed by administering the anti-B7-H3 compound at a dose outside of this range. In some of these embodiments, the method includes administering an anti-B7-H3 compound in an amount sufficient to provide a dose of about 10 μg / kg to about 5 mg / kg to the subject, for example, about 100 μg / kg to about 1 mg / kg.

[0099] A single dose can be administered simultaneously, continuously for a specified time period, or in multiple discrete administrations. When multiple administrations are used, the amount of each administration can be the same or different. For example, a dose of 1 mg per day can be administered as a single administration of 1 mg continuously within 24 hours, as two or more equal administrations (e.g., two 0.5 mg administrations) or as two or more unequal administrations (e.g., 0.75 mg is administered for the first time, and then 0.25 mg is administered for the second time). When multiple administrations are used to deliver a single dose, the intervals between administrations can be the same or different.

[0100] In one or more embodiments, the active ingredient can be administered weekly, for example, in a single dose to multiple doses, although in some embodiments, the method may involve a course of treatment comprising administering a dose of the active ingredient at a frequency outside this range. When a course of treatment involves administering multiple doses over a certain period of time, the amount of each dose may be the same or different. For example, a course of treatment may include a loading dose (e.g., an initial dose), followed by a maintenance dose lower than the loading dose. In addition, when multiple doses are used over a certain period of time, the intervals between doses may be the same or different.

[0101] In certain embodiments, the anti-B7-H3 compound may be administered from about once a month to about five times a week.

[0102] The anti-B7-H3 compound can be administered before, during, or after the subject first exhibits symptoms or clinical signs of the condition. Treatment initiated before the subject first exhibits symptoms or clinical signs associated with the condition can result in a reduced likelihood that the subject will experience clinical evidence of the condition, a reduced severity of the symptoms and / or clinical signs of the condition, and / or complete elimination of the condition, compared to a subject not administered the anti-B7-H3 compound. Treatment initiated after the subject first exhibits symptoms or clinical signs associated with the condition can result in a reduced severity of the symptoms and / or clinical signs of the condition, and / or complete elimination of the condition, compared to a subject not administered the composition.

[0103] The anti-B7-H3 compound can be any embodiment of an anti-B7-H3 compound described herein having an anti-B7-H3 affibody that binds to the extracellular domain of B7-H3 displayed on a target cell of a cell population. In some cases, the target cell can include a tumor cell, and thus the method can include treating a cancer associated with these tumor cells. Thus, in one or more embodiments, the method can include ameliorating at least one symptom or clinical sign of a tumor.

[0104] In embodiments where the target cells include tumor cells, the method may further include surgical removal of the tumor and / or reduction of the size of the tumor by chemotherapy (e.g., chemotherapeutic agents) and / or radiation therapy. Exemplary tumors that may be treated include tumors associated with prostate cancer, lung cancer, colon cancer, rectal cancer, bladder cancer, melanoma, kidney cancer, renal cancer, oral cancer, pharyngeal cancer, pancreatic cancer, uterine cancer, thyroid cancer, skin cancer, head and neck cancer, cervical cancer, ovarian cancer, and / or hematopoietic cancer.

[0105] In one or more embodiments, the anti-B7-H3 compound is administered prior to, concurrently with, or after chemotherapy, surgical resection of a tumor, or radiation therapy.

[0106] In one or more embodiments, the anti-B7-H3 compound can be administered weekly, for example, in a single dose to multiple doses, although in some embodiments, the method can be performed by administering the anti-B7-H3 compound at a frequency outside of this range. In certain embodiments, the anti-B7-H3 compound can be administered from about once a month to about five times a week.

[0107] In one or more embodiments, the method further includes administering one or more additional therapeutic agents. One or more additional therapeutic agents may be administered before, after, and / or simultaneously with the administration of the anti-B7-H3 compound. The anti-B7-H3 compound and the additional therapeutic agent may be administered together. As used herein, the term "co-administered" refers to administering two or more components in a combination so that the therapeutic or preventive effect of the combination may be greater than the therapeutic or preventive effect of any component administered alone. The two components may be co-administered simultaneously or sequentially. The components co-administered simultaneously may be provided in one or more pharmaceutical compositions. Sequential co-administration of two or more components includes administering components so that each component may be present at the same time at the treatment site. Alternatively, sequential co-administration of two components may include at least one component being removed from the treatment site, but at least one cellular effect of administering the component (e.g., cytokine production, activation of a certain cell population, etc.) persists at the treatment site until one or more additional components are administered to the treatment site. Therefore, in some cases, the co-administered combination may include components that have never existed in a chemical mixture with each other. In other embodiments, the anti-B7-H3 compound and the additional therapeutic agent may be administered as part of a mixture (mixture or cocktail). In some aspects, administration of an anti-B7-H3 compound may allow for the effectiveness of lower doses of the other therapeutic modality when compared to administration of one or more other therapeutic agents alone, thereby reducing the likelihood, severity, and / or extent of toxicities observed when higher doses of the one or more other therapeutic agents are administered.

[0108] As used herein, the term "chemotherapeutic agent" refers to any therapeutic agent used to treat cancer. Examples of chemotherapeutic agents include, but are not limited to, dactinomycin, azacitidine, azathioprine, bleomycin, bortezomib, carboplatin, capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, docetaxel, doxifluridine, doxorubicin, epirubicin, epothilone, etoposide, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, irinotecan, nitrogen mustard, mercaptopurine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, pemetrexed, teniposide, thioguanine, topotecan, valrubicin, vinblastine, vincristine, vindesine, vinorelbine, panitumamab, Erbitux TM (cetuximab), matuzumab, IMC-IIF 8, TheraCIM hR3, denosumab, Avastin TM (bevacizumab), Humira TM (adalimumab), Herceptin TM (trastuzumab), Remicade TM (infliximab), rituximab, Synagis TM (Palivizumab), Mylotarg TM (gemtuzumab ozogamicin), Raptiva TM (efalizumab), Tysabri TM (natalizumab), Zenapax TM (Daximab), NeutroSpec TM (technetium (99mTc) fanolesomab), tocilizumab, ProstaScint TM (Indium-Ill-labeled calosomal pendetide), Bexxar TM (Tositumomab), Zevalin TM (ibritumomab tiuxetan conjugated to yttrium-90 (IDEC-Y2B8)), Xolair TM (omalizumab), MabThera TM (rituximab), ReoPro TM (abciximab), MabCampath TM (alemtuzumab), Simulect TM (basiliximab), LeukoScan TM (Thiosomab), CEA-Scan TM (Acitumomab), Verluma TM (nofitumomab), Panorex TM(edrecolomab), alemtuzumab, CDP 870, natalizumab, Gilotrif TM (Afatinib), Lynparza TM (Olaparib), Perjeta TM (Pertuzumab), Otdivo TM (Nivolumab), Bosulif TM (Bosutinib), Cabometyx TM (cabozantinib), Ogivri TM (trastuzumab-dkst), Sutent TM (sunitinib malate), Adcetris TM (vebutuximab), Alecensa TM (Alectinib), Calquence TM (Acalabrutinib), Yescarta TM (ciloleucel), Verzenio TM (Abemaciclib), Keytruda TM (pembrolizumab), Aliqopa TM (copanlisib), Nerlynx TM (neratinib), Imfinzi TM (Durvalumab), Darzalex TM (daratumumab), Tecentriq TM (atezolizumab) or Tarceva TM (Erlotinib). Examples of immunotherapeutic agents include, but are not limited to, interleukins (IL-2, IL-7, IL-12, etc.), cytokines (interferon, G-CSF, etc.), chemokines (CCL3, CCl26, CXCL7), or immunomodulatory imide drugs (imiquimod, thalidomide, etc. or their analogs).

[0109] In one or more embodiments, the method may include administering a sufficient amount of an anti-B7-H3 compound as described herein and administering at least one additional therapeutic agent that exhibits therapeutic synergy. In some aspects of the disclosed methods, a measure of the therapeutic response observed after administration of both an anti-B7-H3 compound as described herein and an additional therapeutic agent is improved relative to the same measure of the therapeutic response observed after administration of either the anti-B7-H3 compound or the additional therapeutic agent alone.

[0110] In another aspect, the present disclosure describes a capture assay device comprising any embodiment of one of the anti-B7-H3 compounds described herein (including anti-B7-H3 affibodies that do not contain additional functional components) immobilized on a substrate. For example, the anti-B7-H3 compounds described herein can be incorporated into cell and / or ligand capture techniques (e.g., ELISA-based assays). The substrate to which the anti-B7-H3 compound is to be immobilized can include, for example, a cell culture plate or dish, a glass slide, or any other support that can be used to perform an assay of an anti-B7-H3 compound that requires immobilization.

[0111] In another aspect, the present disclosure describes a method of using an anti-B7-H3 compound in molecular imaging applications, including, for example, both traditional molecular imaging techniques (e.g., magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), ultrasound, photoacoustic, and fluorescence) and microscopy and / or nanomicroscopy imaging techniques (e.g., total internal reflection fluorescence (TIRF) microscopy, stimulated emission depletion (STRED) nanoscopy, or atomic force microscopy (AFM)).

[0112] The anti-B7-H3 compounds described herein may have in vitro and in vivo detection, diagnosis and / or therapeutic utility. For example, the anti-B7-H3 compound may be included in a detection composition used in a detection method. The detection composition may include any carrier and / or adjuvant as described herein, or any additional carrier or adjuvant known in the art. The method may generally include combining an anti-B7-H3 compound that specifically binds to a target of interest with a sample that includes the target of interest, and then detecting the formation of an anti-B7-H3 compound: target complex. Therefore, the anti-B7-H3 compound may be designed to include a detectable marker, such as a radioisotope, a fluorescent marker, an enzyme, a magnetic marker, or a colorimetric marker.

[0113] In the foregoing description and the claims that follow, the term "and / or" means one or all of the listed elements, or a combination of any two or more of the listed elements; the terms "comprises," "including," and variations thereof are to be interpreted as open ended, i.e., additional elements or steps are optional and may or may not be present; unless otherwise specified, "a," "the," and "at least one" are used interchangeably and mean one or more than one; and numerical ranges expressed as endpoints include all numbers contained within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

[0114] In the foregoing description, for the sake of clarity, specific embodiments may be described separately. References throughout this specification to "one embodiment", "one or more embodiments", "embodiments", "certain embodiments" or "some embodiments" etc. refer to specific features, configurations, compositions or characteristics described in connection with the embodiment that are included in at least one embodiment of the present disclosure. Therefore, the appearance of such phrases throughout this specification does not necessarily refer to the same embodiment of the present disclosure. In addition, specific features, configurations, compositions or characteristics may be combined in one or more embodiments in any suitable manner. Therefore, features described in the context of one embodiment may be combined with features described in the context of different embodiments, unless these features are necessarily mutually exclusive.

[0115] For any method disclosed herein comprising discrete steps, the steps may be performed in any feasible order. Also, any combination of two or more steps may be performed simultaneously, as appropriate.

[0116] The term "administering" is to be understood as providing the pharmaceutical composition in a therapeutically effective amount to a subject in need of treatment.

[0117] As used herein, the terms "preferred" and "preferred" refer to embodiments of the present invention that may provide certain benefits in certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. In addition, the listing of one or more preferred embodiments does not mean that other embodiments are not applicable, nor is it intended to exclude other embodiments from the scope of the present invention.

[0118] The term "polypeptide" refers to a sequence of amino acid residues, regardless of the length of the sequence. Thus, the term "polypeptide" refers to any amino acid sequence of at least two amino acids, and includes full-length proteins, fragments thereof and / or multimeric proteins (as the case may be).

[0119] The term "protein" refers to any sequence of two or more amino acid residues (regardless of the length of the sequence), as well as any complex of two or more independently translated amino acid sequences. Protein also refers to an amino acid sequence that has been chemically modified to include any combination of carbohydrates, lipids, nucleotide sequences, or carbohydrates, lipids, and / or nucleotide sequences. As used herein, "protein," "peptide," and "polypeptide" are used interchangeably.

[0120] As used herein, the term "nucleic acid" or "oligonucleotide" refers to a polynucleotide, such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). Nucleic acids include, but are not limited to, genomic DNA, cDNA, mRNA, iRNA, miRNA, tRNA, ncRNA, rRNA, and recombinantly produced and chemically synthesized molecules, such as aptamers, plasmids, antisense DNA strands, shRNA, ribozymes, nucleic acid conjugates, and oligonucleotides. Nucleic acids can be single-stranded, double-stranded, linear or covalently circular closed molecules. Nucleic acids can be isolated. The term "isolated nucleic acid" refers to a nucleic acid that (i) is amplified in vitro, such as via polymerase chain reaction (PCR), (ii) is produced by cloning and recombination, (iii) is purified, such as by cutting and separation by gel electrophoresis, (iv) is synthesized, such as by chemical synthesis, or (vi) is extracted from a sample. Nucleic acids can be introduced (i.e., transfected) into cells. When RNA is used to transfect cells, the RNA can be modified by stabilization modification, capping, or polyadenylation.

[0121] The present invention is illustrated by the following examples. It is to be understood that the specific examples, materials, amounts and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as described herein.

[0122] Example

[0123] Example 1

[0124] Library design

[0125] Affibody library design followed Woldring's gradient site-wise library design, where the amino acid diversity at possible hotspot positions was guided by the amino acid prevalence in natural antibody interfaces and previously evolved affibodies (Woldring et al., Biochemistry 56, 1656–1671 (2017)).

[0126] Discovery and Evolution Strategies

[0127] Yeast surface display is used to display the affibody library, and magnetic activated cell sorting (MACS) and fluorescence activated cell sorting (FACS) are used to select B7-H3 binders. The population is sorted to achieve detectable binding at 50nM B7-H3 target. The DNA is then isolated from the yeast, and random mutagenesis of the paratope and the entire affibody gene is performed via error-prone polymerase chain reaction (PCR). The DNA is electroporated back into yeast for display and further sorted until binding to low nanomolar concentrations of B7-H3 is observed.

[0128] MACS selection with soluble extracellular domain

[0129] Magnetic bead selection was performed using at least 15-fold oversampling of affinity diversity at all stages. Biotinylated recombinant human B7-H3 extracellular domain (available from Sino Biological, Inc., Beijing, China) for forward separation and biotinylated Renilla green fluorescent protein (rrGFP; available from Avidity, LLC, Aurora, CO) for depletion were incubated with DYNABEADS biotin binder (Invitrogen, Thermo Fisher Scientific, Inc., Waltham, MA) to coat beads with protein. Yeast was subjected to magnetic activated cell sorting, where yeast was incubated with control naked biotin binder beads at 4°C for two hours, followed by another two-hour incubation with GFP-labeled beads for depletion to remove any nonspecific and non-B7-H3 binding interactions. The yeast was then incubated with beads with fixed recombinant human B7-H3 target protein for another two hours. The bound yeast was positively selected. MACS was performed at 4°C and the yeast were washed twice between incubations. A total of three MACS selections of increasing wash stringency were performed, with yeast cultured and induced between each sort. Additional MACS sorts were performed on large mutation-untreated libraries following error-prone PCR, similar to the procedure described previously.

[0130] FACS selection with soluble extracellular domain

[0131] After three MACS sortings of the affinity library, the library size can be easily sampled via FACS. The induced yeast population was simultaneously labeled with mouse anti-c-Myc antibody (BioLegend, San Diego, CA) and 50nM biotinylated recombinant human B7-H3 extracellular domain at 4°C for 30 minutes. The cells were washed once with PBSA, labeled with goat anti-mouse Alexa Fluor647 conjugate (Thermo Fisher Scientific, Inc., Waltham, MA) and streptavidin Alexa Fluor488 conjugate (Thermo Fisher Scientific, Inc., Waltham, MA) at 4°C for 20 minutes, and washed with PBSA. Cells that were Myc positive and had B7-H3 signals above background were collected.

[0132] Error-prone PCR with Affibody

[0133] Affibodies were randomly mutated by error-prone PCR with mutagenic analogs 8-oxo-dGTP and dPTP. Zymoprepped plasmid DNA was mutated by error-prone PCR of the full affibodies gene using primers W5 / W3 and error-prone PCR of the affibodies helix using primers ABY1F-b / ABY1R and ABY2F / ABY2R-b19. PCR products were purified by agarose gel electrophoresis. Affibodies helix genes were assembled into one construct using PCR assembly. The final gene insert was amplified by PCR, concentrated by ethanol precipitation, and resuspended for electroporation. The mutated affibodies library was homologously recombined with linearized pCT-40-Helix to transform the affibodies helix into EBY100 yeast by electroporation. Electroporation produced approximately 200 million transformants of the affibodies library.

[0134] Monovalent MACS sorting with soluble extracellular targets

[0135] After MACS sorting of the large mutant untreated library, the yeast was subjected to a more stringent monovalent MACS sort. As before, the yeast was incubated with control naked biotin-bound beads, washed, and then depleted with GFP-coated beads. The yeast was then washed and incubated with 100 nM biotinylated recombinant human B7-H3 extracellular domain for one hour. Naked biotin-bound beads were spiked in to bind biotinylated B7-H3 and incubated for another two hours at 4°C. The beads were washed three times and yeast that were still bound were collected.

[0136] Preparation of detergent-solubilized MS1-B7-H3 cell lysate

[0137] Mile Sven 1 cells stably transfected to express human B7-H3 (MS1-B7-H3) were grown in DMEM containing 10% fetal bovine serum (v / v) and 1% penicillin and streptomycin at 37°C and 5% CO2. MS1-B7-H3 cells were cultured at 75 cm 2 The cells were grown to 70-90% confluence in tissue culture treated flasks. The cells were washed with PBS and detached by trypsin-EDTA treatment for five minutes, quenched with serum-containing medium, and pelleted at 500×g for three minutes. The pelleted cells were washed twice and resuspended in PBS containing 0.5 mg / mL fresh sulfo-NHS-biotin (Thermo Fisher Scientific, Inc., Waltham, MA) for 30 minutes at room temperature. After incubation, the cells were washed twice to remove excess biotin and lysed in 250 μL lysis buffer at 4°C for 15 minutes. Cell debris was pelleted at 10,000×g for 30 minutes and removed.

[0138] FACS selection using detergent-solubilized cell lysates

[0139] The affinity body library was selected by two rounds of flow cytometry with detergent-dissolved cell lysate. The library was washed once with PBSA and incubated with cell lysate for one hour at 4°C. After incubation, the yeast was washed and incubated with chicken anti-Myc-FITC (Immunology Consultants Laboratory Inc., Portland, OR) and streptavidin, Alexa Fluor 647 conjugate (Thermo Fisher Scientific, Inc., Waltham, MA) at 4°C for 20 minutes and washed again. FACS was used to collect yeast with the highest MS1-B7-H3 lysate binding (AF647): Myc (FITC) ratio that was Myc positive (FITC). The sorting was repeated with higher stringency by using a lower B7-H3 lysate concentration.

[0140] FACS selection with protease and thermostability assays

[0141] The yeast induced to display the Affimer was washed and incubated with proteinase K (1×10 -6 Units / μL; available from New England Biolabs, Inc., Ipswich, MA) at 55°C for 10 minutes and then immediately placed on ice. The yeast was then incubated with MS1-B7-H3 cell lysate for one hour at 4°C. After incubation, the yeast was washed, incubated with chicken anti-Myc-FITC and streptavidin-AlexaFluor 647 conjugate at 4°C for 20 minutes, and washed again. FACS was used to collect Myc-positive (FITC) yeast with the highest MS1-B7-H3 lysate binding (AF647): Myc (FITC) ratio.

[0142] Sanger sequencing of yeast PCR products

[0143] The enriched B7-H3 binding population was plated onto SD-CAA plates and grown for two days. Ten colonies from the Affibody library were randomly selected and incubated in 50 μL of distilled water at 100°C for five minutes. Two microliters of yeast sample were taken and PCR was performed with GeneAmp5 / 3 primers and DNA purification was performed. The amplified Affibody gene and GeneAmp5 primer were sent to Eurofins Genomics LLC for Sanger sequencing.

[0144] Cloning, protein expression and purification

[0145] The affinity body coding region in the DNA recovered from the final B7-H3 flow cytometry sorting was amplified by PCR, digested with NheI-HF and BamHI-HF restriction enzymes (New England Biolabs, Inc., Ipswich, MA), and connected to the pET-24b vector containing a C-terminal six-histidine tag with T4 DNA ligase. The plasmid was transformed into T7 Express competent Escherichia coli and plated on a lysing broth (LB) plate containing 50mg / L kanamycin. Sanger sequencing was performed on the transformant for the full-length gene, and the appropriate transformant was grown at 37°C for 12-16 hours at 250rpm in 5mL liquid LB containing kanamycin (50mg / L). Saturated culture was added to 100mL LB, grown and induced. The cells were pelleted and resuspended in lysis buffer (50 mM sodium phosphate (pH 8.0), 0.5 M sodium chloride, 5% glycerol, 5 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate and 25 mM imidazole), frozen and thawed five times to lyse the cells, centrifuged at 4°C for 10 minutes, and filtered through 0.25 mm. The resulting cell lysate was passed through a 0.25 mL Cobalt HisPur resin volume centrifugal column, washed with 30 mM imidazole, and eluted with 300 mM imidazole. Affibody purity and concentration were analyzed via protein gel electrophoresis.

[0146] Affinity titration

[0147] The isolated MS1-B7-H3 cells were washed and labeled with different concentrations of purified Affimer and Affimer fusions at 4°C for at least 30 minutes. The cells were pelleted at 500 × g for three minutes and washed with cold PBSA, then labeled with anti-His6FITC conjugate (available from Abcam, Cambridge, United Kingdom) at 4°C for 20 minutes. Fluorescence was analyzed using ACCURI C6 Plus. Dissociation constants were calculated by nonlinear least squares regression using a 1:1 binding model in PRISM software (GraphPad Software, San Diego, CA).

[0148] Analyzing the modularity of Affibodies

[0149] Affibody gene coding region is amplified by PCR, and is assembled into pET-24b vector via NEBuilder HiFi DNA Assembly (New England Biolabs, Inc., Ipswich, MA), and the pET-24b vector contains GSGGGSGGGKGGGGT (SEQ ID NO:35) joint and amino acid 60-206 of sortase A (EC3.4.22.70) gene with C-terminal hexa-histidine tag. Plasmid is transformed into BL21-CodonPlus (DE3)-RIL competent intestinal bacteria, and is plated onto LB plate containing 50mg / L kanamycin. For full-length gene, transformant is carried out Sanger sequencing, and appropriate transformant is grown in 50mg / L kanamycin and chloramphenicol, for bacterial growth and protein purification. Purified protein is subjected to affinity titration, to assess the binding affinity of selected affibody in the presence of conjugated protease.

[0150] Embodiment 2:

[0151] Example 2 describes the affinity maturation, specificity maturation and stability maturation of the 1.5 Affibody population of Example 1.

[0152] Error-prone PCR

[0153] DNA was isolated from a 1.5 yeast population and random mutagenesis of the variable regions of the Affimers was performed via error-prone polymerase chain reaction (PCR). The DNA was electroporated back into yeast for display and further sorted using the following sorting schemes: (1) affinity sorting (lysate MACS with 1 pmol B7-H3+ lysate); (2) affinity sorting (stringent K d FACS sorting); (3) specificity sorting (multi-target MACS depletion sorting); and (4) stability sorting (thermolysin FACS sorting at 55°C). After each sorting, the population was deeply sequenced, filtered via USEARCH (Ultra-rapid Sequencing Analysis; Robert C. Edgar, Search and clustering orders of magnitude faster than BLAST, Bioinformatics, Vol. 26, No. 19, Oct. 1, 2010, pp. 2460–2461, doi.org / 10.1093 / bioinformatics / btq461), and filtered for full-length affibody variants.

[0154] The frequency of each sequence in each bin (e.g., affinity, avidity, specificity, and stability) was determined, as well as their subsequent enrichment. If a read count was 0, a read count of 1 was assigned. Z scores for affinity, specificity, stability, and final frequency were determined, and a final conditional weighted average z score was calculated. The best performers were selected based on the highest scores.

[0155] The conditional weighted average z score is calculated by first determining the frequency of each variant in each sorting. The affinity, specificity and stability sorting enrichment values ​​of each variant are then calculated by dividing the frequency of a single variant in a specific sorting by its frequency in the previous sorting. Its z score is calculated by (sorting enrichment score-average sorting enrichment score of all variants) divided by (standard deviation of sorting enrichment scores of all variants). The z score is averaged according to the following weights: affinity=1; frequency=3; specificity=2; and stability=1. The final frequency and specificity z scores are the most important because they are given the greatest weight. In addition, the following conditions are also included: affinity enrichment>0.5 and final frequency>0. Affinity enrichment values ​​greater than 1 indicate enrichment. A value of 0.5 is selected to explain variants that initially exist at a higher frequency and may not have the opportunity to be enriched. The final frequency condition is included because the variant must be present in the population of the final sequencing.

[0156] Figure 6 The z scores for affinity, specificity, stability, and final frequency of the top 13 variants are shown, as well as the conditional weighted average z score. Values ​​greater than 1 indicate enrichment, while values ​​less than 1 indicate depletion. Figure 6 The color bar in the figure indicates the affinity range M–M+2SD enrichment, while specificity and stability are shown as 1–M+2SD because the mean (M) is slightly less than 1. Figure 6 On bar graphs, z-scores are displayed on a scale of 1-10 (i.e., if the z-score is 10 or higher, the bar spans the entire length of the graph).

[0157] B7-H3 cell lysate MACS sorting (affinity sorting):

[0158] Affinity sorting was performed. This sorting is considered affinity sorting because the B7-H3 target is expressed multivalently on the avidin beads, not just monovalently in solution. The yeast also expresses thousands of affimers per cell, so avidity binding can occur between the yeast and the B7-H3 coated beads.

[0159] Magnetic bead selection was performed with 20-fold oversampling to select for B7-H3 binders and to easily eliminate unbinders / truncated Affibodies generated by error-prone PCR. Yeast was incubated with naked streptavidin-coated beads at 4°C for two hours, followed by another two-hour incubation with GFP-coated beads for depletion. Yeast was incubated with 1 pmol of detergent-dissolved biotinylated MS1-B7-H3 cell lysate for another two hours. Typically, 33 pmol of antigen is used to coat streptavidin beads; however, 1 pmol was selected to be more stringent (e.g., to reduce affinity). Bound yeast was selected and grown. Biotinylation of MS1-B7-H3 cell lysate is nonspecific and reacts to all proteins (nonspecific N-hydroxysuccinimide (NHS) chemistry), not just B7-H3. B7-H3 is expressed at approximately 1 million per cell, and the Affibody library is ready to bind to B7-H3.

[0160] Strict K d FACS sorting (affinity sorting)

[0161] After a round of B7-H3 cell lysate MACS sorting, the library size can be easily sampled via FACS. The induced yeast population was labeled with approximately 0.2 nM biotinylated B7-H3 cell lysate for two hours, washed, and labeled with streptavidin-AF647 and chicken anti-Myc-FITC. The top 0.4% of cells (highest affinity) were collected for the next sorting (specific sorting).

[0162] Multi-target MACS depletion (specific sorting)

[0163] In order to select more specific binders, the population separated after affinity sorting was subjected to multi-target depletion. The following proteins were biotinylated, incubated with streptavidin-coated beads, and used for negative depletion: lysozyme, bovine serum albumin, human interleukin receptor 2γ, tobacco etch virus (TEV) protease, human urokinase-type plasminogen activator receptor, human carbonic anhydrase II, and rabbit IgG-FITC. These proteins were used because they are easy to obtain and / or have been conjugated with biotin. Yeast was incubated at 4°C for two hours with the above proteins coated on beads. The yeast was then subjected to the same negative depletion step again. This is to increase the confidence that non-specific binders are depleted. Unbound yeast was selected and grown for the next sorting (stability sorting).

[0164] Thermolysin stability FACS sorting (stability sorting)

[0165] To select stable binders, the affinity body population after specific sorting was incubated with protease at elevated temperature. Yeast was induced to display the affinity body population and incubated with 0.75 mg / mL thermolysin at 55°C for 10 minutes and then immediately placed on ice. The yeast was washed and incubated with mouse anti-MYC and rabbit anti-HA-biotin for 20 minutes. The yeast was washed again and labeled with goat anti-mouse AF647 and streptavidin-FITC for another 20 minutes. Yeast that was HA and Myc positive was sorted with a three-layer gating method, where the top 2%, 14%, and 19% of the display yeast were collected using FACS.

[0166] Deep sequencing was performed by ISEQ (Illumina, San Diego, CA)

[0167] The sorted affibody population was deep sequenced, filtered via USearch, and further filtered for full-length affibodies. In the stability sort, three layers of gates were collected and sequenced. Due to insufficient sequencing depth for full-length affibodies, the read counts from each stability gate were summed to obtain the total stability read count. Clones that reproduced the previously engineered B7-H3 affibodies were removed for sequence analysis.

[0168] The complete disclosures of all patents, patent applications, and publications cited herein, as well as electronically available materials (including, for example, nucleotide sequence submissions in, for example, GenBank and RefSeq, and amino acid sequence submissions in, for example, SwissProt, PIR, PRF, PDB, and translations of annotated coding regions from GenBank and RefSeq) are incorporated by reference in their entirety. If there is any inconsistency between the disclosure of the present application and the disclosure of any document incorporated by reference herein, the disclosure of the present application shall prevail. The foregoing detailed description and examples are given only for clarity of understanding. No unnecessary limitations should be understood from this. The present invention is not limited to the exact details shown and described, as variations obvious to those skilled in the art will be included in the invention defined by the claims.

[0169] Unless otherwise indicated, all numbers indicating quantities of components, molecular weights, etc. used in the specification and claims are to be understood as being modified in all instances by the term "about". Therefore, unless otherwise indicated to the contrary, the numerical parameters set forth in the specification and claims are approximate values ​​that may vary depending upon the desired properties intended to be obtained by the present invention. At the very least, and not as an attempt to limit the concept of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.

[0170] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values ​​set forth in the specific examples are reported as precisely as possible. All numerical values, however, inherently contain ranges necessarily resulting from the standard deviations found in their respective testing measurements.

[0171] All headings are for the convenience of the reader and should not be used to limit the meaning of the text following the heading unless so specified.

[0172] Sequence Listing Free Text

[0173] SEQ ID NO:1-ABY

[0174] AEAKYAKEQQ NAFYEILHLP NLTEEQRNAF IQKLKDDPSQ SSELLSEAKKL NDSQAPK

[0175] SEQ ID NO:2—General consensus sequence

[0176] AEAKYXKEXX XAXXXIXXLP NLXXXQXXAF XXXLXXDPSQ SSELXXEAXK LNDSQAPK

[0177] X6: Y, N, S, T, D or A;

[0178] X9: L, R, K, W, D, I, N or Q;

[0179] X 10 :H,A,S,F,I,D,E,Q,T,N or L;

[0180] X 11 :T,Y,D,A,L,P,I or N;

[0181] X 13 :I,Y,L,V,T or F;

[0182] X 14 :Q,Y,L,V,G,F,E,A,M or S;

[0183] X 15 :V,S,Q or E;

[0184] X 17 :H,A,V,G,R,I,F or L;

[0185] X 18 :S,Y,L,G,T,N,M,D,R,W,E or H;

[0186] X 23 :T or A;

[0187] X 24 :L,K,A,G,R,H,W,V or E;

[0188] X 25 :D,P,T,N,V,S,H,L,R,A,W or E;

[0189] X 27 :R,K,T,I or A;

[0190] X 28 :A,Y,R,N,D,Q,I,H,L,S or F;

[0191] X 31 :L,K,I or T;

[0192] X 32 :L,G,Y,R,A,F,V,S or Q;

[0193] X 33 :A or K;

[0194] X 35 :F,S,V,H,Y,D,E or K;

[0195] X 36 :N or D;

[0196] X 44 :L or F;

[0197] X 46 :S or P;

[0198] X 49 :R or K.

[0199] The second consensus sequence of SEQ ID NO:3-SEQ ID NO:4 to SEQ ID NO:18

[0200] AEAKYYKELH NAIGVIRSLP NLTRDQRAAF LLALFNDPSQ SSELLSEAKKL NDSQAPK

[0201] SEQ ID NO:4-ABY 0.4.1

[0202] AEAKYYKELH NAIQVIHYLP NLTLDQKYAF KLALFNDPSQ SSELLSEAKK LNDSQAPK

[0203] SEQ ID NO:5-ABY 0.4.2

[0204] <h2 style=";text-align:left;direction:ltr">AEAKYNKELA TAYYVIALLP NLTEPQRAAF LGALSDDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0205] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:6-ABY 0.4.3<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0206] <h2 style=";text-align:left;direction:ltr"> AEAKYYKELH TAILSIHGLP NLTKTQKRAF IYALFNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0207] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:7-ABY 0.4.4<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0208] <h2 style=";text-align:left;direction:ltr"> AEAKYNKERS YAIYQIVLLP NLTANQRNAF LRALVDDPSQ SSELLSEAK KLNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0209] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:8-ABY 0.4.5<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0210] <h2 style=";text-align:left;direction:ltr"> AEAKYSKEKF DAILSILSLP NLTAVQRDAF LGALHDDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0211] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:9-ABY 0.4.6<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0212] <h2 style=";text-align:left;direction:ltr"> AEAKYYKELH YAIVSIRGLP NLTASQRIAF LFALFNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0213] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:10-ABY 0.4.7<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0214] <h2 style=";text-align:left;direction:ltr"> AEAKYTKEWI AAYLQIGYLP NLTGVQRQAF TAALYNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0215] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:11-ABY 1.4.1<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0216] <h2 style=";text-align:left;direction:ltr"> AEAKYDKEKS NAILSIVTLP NLTRVQRHAF LVALHNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0217] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:12-ABY 1.4.2<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0218] <h2 style=";text-align:left;direction:ltr">AEAKYYKELH DAIVQIRNLP NLTRPQRAAF KLALFNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0219] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:13-ABY 1.4.3<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0220] <h2 style=";text-align:left;direction:ltr"> AEAKYYKELH NAIGVIRSLP NLTRHQRAAF LLALFNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0221] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:14-ABY 1.4.4<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0222] <h2 style=";text-align:left;direction:ltr"> AEAKYDKERL NAIFQIVLLP NLTRDQKLAF TAALYDDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0223] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:15-ABY 1.4.5<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0224] <h2 style=";text-align:left;direction:ltr"> AEAKYYKELH NAIQVIHYLP NLTRDQKYAF KLALFNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0225] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:16-ABY 1.4.6<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0226] <h2 style=";text-align:left;direction:ltr"> AEAKYYKELH NAIGVIRSLP NLTRDQRYAF KLALFNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0227] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:17-ABY 1.4.7<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0228] <h2 style=";text-align:left;direction:ltr"> AEAKYYKELH NAIGVIRSLP NLTHHQRSAF LLALFNDPSQ SSELLSEARK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0229] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:18-ABY 1.4.8<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0230] <h2 style=";text-align:left;direction:ltr"> AEAKYYKELH NAIGVIRSLP NLTHHQKSAF LLALFNDPSQ SSELLPEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0231] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:19–ABY 1.5.1<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0232] <h2 style=";text-align:left;direction:ltr">AEAKYYKELH NAIGVIRSLP NLTRHQRAAF LLALFNDPSQ SSELLSEAKKL NDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0233] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:20–ABY 1.5.2<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0234] <h2 style=";text-align:left;direction:ltr"> AEAKYYKELH DAIQVIHYLP NLTLDQKYAF KLALFNDPSQ SSELLSEAKKL NDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0235] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:22–Otu13<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0236] <h2 style=";text-align:left;direction:ltr"> AEAKYAKELD NAYYEIVTLP NLTWLQTFAF IFALDNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0237] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:23–Otu8<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0238] <h2 style=";text-align:left;direction:ltr"> AEAKYAKELH NAIGVIRSLP NLTRHQRAAF LLALFNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0239] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:24–Otu12<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0240] <h2 style=";text-align:left;direction:ltr"> AEAKYYKELH DAIQVIHYLP NLTRRQRAAF KLALFNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0241] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:25–Otu15<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0242] <h2 style=";text-align:left;direction:ltr"> AEAKYAKEKS NAVLSIVSLP NLTRAQRHAF LVALHNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0243] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:26–Otu11<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0244] <h2 style=";text-align:left;direction:ltr"> AEAKYNKEDS NAYEEI IMLP NLTVWQILAF IVALDNDPSQ SSELLSEAKK LNDSQAPK<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0245] <h2 style=";text-align:left;direction:ltr"> SEQ ID NO:27–Otu89<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">

[0246] <h2 style=";text-align:left;direction:ltr"> AEAKYDKELE LAYLEIFDLP NLTWLQTFAF ISALENDPSQ SSELLSEAKK LNDSQAPK

[0247] SEQ ID NO:28 - Otu227

[0248] AEAKYAKELEP ALAEILRLP NLTWLQTIAF ILALEDDPSQ SSELLSEAKK LNDSQAPK

[0249] SEQ ID NO:29 - Otu1607

[0250] AEAKYYKEKS NAVLSIVSLP NLARAQRAA FLVALHDDPSQ SSEFLSEAKK LNDSQAPK

[0251] SEQ ID NO:30 - Otu225

[0252] AEAKYAKEDQ NALSEILWLP NLTGWQTFA FILALENDPSQ SSELLSEAKK LNDSQAPK

[0253] SEQ ID NO:31 - Otu394

[0254] AEAKYYKELH NAIGVIRSLP NLTRHQRTAF LLALFNDPSQ SSELLSEAKK LNDSQAPK

[0255] SEQ ID NO:32 - Otu249

[0256] AEAKYAKEIE IAYVEILLLP NLTWLQTYAF IFALEDDPSQ SSELLSEAKK LNDSQAPK

[0257] SEQ ID NO:33 - Otu252

[0258] AEAKYAKENT IALMEIIELP NLTLLQTLAF IVALDDDPSQ SSELLSEAKK LNDSQAPK

[0259] SEQ ID NO:34 - Otu265

[0260] AEAKYDKELN IATMEILTLP NLTLWQAIAF IVALDDDPSQ SSELLSEAKK LNDSQAPK

[0261] SEQ ID NO:35 - Adapter

[0262] GSGGGSGGGK GGGGT

[0263] SEQ ID NO:36—Linker

[0264] GGGGSGGGGS GGGGS

[0265] SEQ ID NO:37—Linker

[0266] GSTSGSGKPG SGEGSTKG

[0267] SEQ ID NO:38—Linker

[0268] PSGQAGAAAS ESLFVSNHAY

[0269] SEQ ID NO:39—Linker

[0270] EASGGPE

[0271] SEQ ID NO:40—Linker

[0272] AEAAKEAAKE AAKEAAKALE AEAAKEAAKE AAKEAAKA

[0273] SEQ ID NO:41—Linker

[0274] AEAAKEAAKA

[0275] SEQ ID NO:42—Linker

[0276] SGGGGSGGGGS GGGGSGGGGSG

[0277] SEQ ID NO:43—Linker

[0278] GGGGSGGGGS

[0279] SEQ ID NO:44—Linker

[0280] GSTSGSGKPG SGEGSTKG

[0281] SEQ ID NO:45—Linker

[0282] EPKSSDKTHT SPPSP

[0283] SEQ ID NO:46—Linker

[0284] RATPSHNSHQ VPSAGGPTAN SGTSG

[0285] SEQ ID NO:47—Linker

[0286] SSGGGGSGGG GGGSSRSSL

Claims

1. An anti-B7-H3 compound, comprising an anti-B7-H3 affibody, wherein the anti-B7-H3 affibody comprises: SEQ ID NO: 2; An amino acid sequence having at least 90% sequence similarity to SEQ ID NO: 2; or An amino acid sequence having at least 90% sequence identity to SEQ ID NO:

2.

2. The anti-B7-H3 compound according to claim 1, wherein the anti-B7-H3 affibody comprises: Any one of SEQ ID NO:3 to SEQ ID NO:20 or SEQ ID NO:22 to SEQ ID NO:34; An amino acid sequence having at least 90% sequence similarity to any one of SEQ ID NO:3 to SEQ ID NO:20 or SEQ ID NO:22 to SEQ ID NO:34; or An amino acid sequence having at least 90% sequence identity to any one of SEQ ID NO:3 to SEQ ID NO:20 or SEQ ID NO:22 to SEQ ID NO:

34.

3. The anti-B7-H3 compound according to any one of the preceding claims, further comprising a first functional component operably linked to the anti-B7-H3 affibody.

4. The anti-B7-H3 compound according to claim 3, wherein the first functional component comprises a targeting component, an imaging component, an enzyme or a small molecule drug.

5. The anti-B7-H3 compound of claim 4, wherein the targeting component binds to the extracellular domain of a protein displayed on natural killer cells or T cells.

6. The anti-B7-H3 compound of claim 4, wherein the imaging component comprises a colorimetric label, a fluorescent label, a radioactive label, a magnetic label or an enzyme label.

7. The anti-B7-H3 compound of claim 4, wherein the enzyme comprises sortase A.

8. The anti-B7-H3 compound according to claim 4, wherein the small molecule drug comprises one or more radioactive isotopes.

9. The anti-B7-H3 compound according to any one of the preceding claims, further comprising a second functional component operably linked to the anti-B7-H3 affibody.

10. The anti-B7-H3 compound according to claim 9, wherein the second functional component comprises a targeting component, an imaging component, an enzyme or a small molecule drug.

11. The anti-B7-H3 compound of claim 9, wherein the first functional component is directly linked to the anti-B7-H3 affibody and the second functional component is directly linked to the anti-B7-H3 affibody.

12. The anti-B7-H3 compound of claim 9, wherein the first functional component is directly linked to the anti-B7-H3 affibody and the second functional component is directly linked to the first functional component.

13. A composition comprising: The anti-B7-H3 compound according to any one of the preceding claims; as well as A pharmaceutically acceptable carrier.

14. A method comprising administering to a subject a composition according to claim 13.

15. The method of claim 14, wherein the subject has or is at risk of having a tumor.

16. The method of claim 14, wherein the subject has or is at risk of having cancer.

17. The method of claim 14, wherein the composition is administered prior to, concurrently with, or after chemotherapy, surgical resection of a tumor, or radiotherapy.

18. The method of claim 14, further comprising a detection imaging component to detect an anti-B7-H3 compound that binds to B7-H3 expressed by the cell.

19. The method of claim 18, wherein the cell is a cancer cell expressing B7-H3.

20. The method of claim 18 or 19, wherein the imaging component is detectable by positron emission tomography.

Citation Information

Cited By

  • B7-H3-based bimodal imaging probe as well as preparation method and application thereof

    CN120478677A